{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:44:35Z","timestamp":1792147475872,"version":"4.4.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nanomedicine has become an important translational platform in oncology by enabling altered pharmacokinetics, controlled exposure, reduced systemic toxicity, intracellular delivery of nucleic acids, and improved handling of complex therapeutic payloads. Early cancer nanomedicines, including pegylated liposomal cytotoxics and albumin-bound drug products, demonstrated that nanoscale formulation design could improve the clinical utility of established anticancer agents. More recently, lipid nanoparticles, RNA therapeutics, individualized neoantigen vaccines, gene-regulatory approaches, and immune-modulating delivery systems have expanded the role of nanoparticles from passive drug carriers to programmable oncology platforms. This narrative review examines the developmental evolution of cancer-focused pharmaceutical nanoparticles, with emphasis on liposomes, lipid nanoparticles (LNPs), albumin-bound systems, polymeric particles, polymeric micelles, nanocrystals, nanoemulsions, solid lipid nanoparticles, inorganic particles, extracellular vesicles, and hybrid delivery technologies. Each platform class is treated systematically, covering representative approved products, formulation characteristics, route of administration, clinical evidence, and the specific development risks that limit it. There view connects platform design with oncology-specific barriers, including tumor heterogeneity, variable enhanced permeability and retention (EPR) effects, dense extracellular matrix, abnormal tumor vasculature, mononuclear phagocyte clearance, protein-corona formation, endosomal escape, immune activation, and the difficulty of translating animal tumor models into clinical benefit. These barriers are organized as a sequential delivery cascade, and the behavior of each platform class is compared step by step rather than described as a set of universal phenomena. Nanoparticle candidates that accumulated well in preclinical tumors but failed in clinical trials are examined alongside approved products, because the contrast between the two is where most of the transferable lessons sit. A product-development perspective is used to discuss critical quality attributes (CQAs), manufacturing scalability, potency testing, sterility strategy, stability, release methods, regulatory expectations, commercial feasibility, and clinical differentiation. A development-to-translation framework is proposed for comparing cancer nanomedicine platforms across formulation maturity, analytical maturity, manufacturing maturity, biological rationale, clinical evidence, regulatory readiness, and commercial feasibility; regulatory and commercial maturity are scored separately, the criteria behind each level are defined explicitly, and the resulting rankings are presented as a heuristic aid to discussion rather than a validated quantitative metric. Future progress in oncology nanomedicine will depend not only on novel materials or targeting claims, but also on disciplined product design, biologically meaningful potency assays, scalable manufacturing, patient-selection strategies, and clear integration with precision oncology.<\/jats:p>","DOI":"10.1186\/s43046-026-00418-y","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:48:24Z","timestamp":1792144104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer nanomedicine and RNA\/Lipid nanoparticle platforms in oncology: developmental evolution, translational barriers, and precision-therapy opportunities"],"prefix":"10.1186","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8410-7361","authenticated-orcid":false,"given":"Bhasker","family":"sambar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5390-9724","authenticated-orcid":false,"given":"Anil Kumar","family":"Dudam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"2","key":"418_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"418_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337. https:\/\/doi.org\/10.1038\/nrc.2016.108.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"418_CR3","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","volume":"33","author":"D Bobo","year":"2016","unstructured":"Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373\u201387. https:\/\/doi.org\/10.1007\/s11095-016-1958-5.","journal-title":"Pharm Res"},{"issue":"3","key":"418_CR4","doi-asserted-by":"publisher","first-page":"e10143","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3):e10143. https:\/\/doi.org\/10.1002\/btm2.10143.","journal-title":"Bioeng Transl Med"},{"key":"418_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jconrel.2020.07.007","volume":"326","author":"M Germain","year":"2020","unstructured":"Germain M, Caputo F, Metcalfe S, et al. Delivering the power of nanomedicine to patients today. J Control Release. 2020;326:164\u201371. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.007.","journal-title":"J Control Release"},{"issue":"2","key":"418_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil: the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020.","journal-title":"J Control Release"},{"issue":"1","key":"418_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36\u201348. https:\/\/doi.org\/10.1016\/j.addr.2012.09.037.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"418_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","volume":"9","author":"U Bulbake","year":"2017","unstructured":"Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. https:\/\/doi.org\/10.3390\/pharmaceutics9020012.","journal-title":"Pharmaceutics"},{"key":"418_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","volume":"108","author":"JI Hare","year":"2017","unstructured":"Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25\u201338. https:\/\/doi.org\/10.1016\/j.addr.2016.04.025.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"418_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","volume":"14","author":"N Desai","year":"2012","unstructured":"Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282\u201395. https:\/\/doi.org\/10.1208\/s12248-012-9339-4.","journal-title":"AAPS J"},{"key":"418_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-med-040210-162544","volume":"63","author":"AZ Wang","year":"2012","unstructured":"Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185\u201398. https:\/\/doi.org\/10.1146\/annurev-med-040210-162544.","journal-title":"Annu Rev Med"},{"key":"418_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","volume":"200","author":"A Wicki","year":"2015","unstructured":"Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138\u201357. https:\/\/doi.org\/10.1016\/j.jconrel.2014.12.030.","journal-title":"J Control Release"},{"key":"418_CR13","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat Rev Mater"},{"issue":"11","key":"418_CR14","doi-asserted-by":"publisher","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","volume":"15","author":"R Tenchov","year":"2021","unstructured":"Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles: from liposomes to mRNA vaccine delivery. ACS Nano. 2021;15(11):16982\u20137015. https:\/\/doi.org\/10.1021\/acsnano.1c04996.","journal-title":"ACS Nano"},{"issue":"4","key":"418_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines: a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379. https:\/\/doi.org\/10.1038\/nrd.2017.243.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"418_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","volume":"37","author":"Y Weng","year":"2019","unstructured":"Weng Y, Xiao H, Zhang J, Liang XJ, Huang Y. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019;37(5):801\u201325. https:\/\/doi.org\/10.1016\/j.biotechadv.2019.04.012.","journal-title":"Biotechnol Adv"},{"key":"418_CR17","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120586.","journal-title":"Int J Pharm"},{"issue":"7","key":"418_CR18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25(7):1467\u201375. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.013.","journal-title":"Mol Ther"},{"issue":"10427","key":"418_CR19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)02268-7.","journal-title":"Lancet"},{"issue":"7963","key":"418_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"key":"418_CR21","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, et al. RNA neoantigen vaccines prime long-lived CD8\u2009+\u2009T cells in pancreatic cancer. Nature. 2025;639:1042\u201351. https:\/\/doi.org\/10.1038\/s41586-024-08508-4.","journal-title":"Nature"},{"issue":"7662","key":"418_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217\u201321. https:\/\/doi.org\/10.1038\/nature22991.","journal-title":"Nature"},{"issue":"7662","key":"418_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136. https:\/\/doi.org\/10.1038\/nature23003.","journal-title":"Nature"},{"issue":"7823","key":"418_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107\u201312. https:\/\/doi.org\/10.1038\/s41586-020-2537-9.","journal-title":"Nature"},{"issue":"12 Pt 1","key":"418_CR25","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387\u201392.","journal-title":"Cancer Res"},{"issue":"1","key":"418_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","volume":"65","author":"H Maeda","year":"2013","unstructured":"Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71\u20139. https:\/\/doi.org\/10.1016\/j.addr.2012.10.002.","journal-title":"Adv Drug Deliv Rev"},{"issue":"Pt A","key":"418_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","volume":"244","author":"F Danhier","year":"2016","unstructured":"Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244(Pt A):108\u201321. https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.015.","journal-title":"J Control Release"},{"key":"418_CR28","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014. https:\/\/doi.org\/10.1038\/natrevmats.2016.14.","journal-title":"Nat Rev Mater"},{"issue":"5","key":"418_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","volume":"19","author":"S Sindhwani","year":"2020","unstructured":"Sindhwani S, Syed AM, Ngai J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19(5):566\u201375. https:\/\/doi.org\/10.1038\/s41563-019-0566-2.","journal-title":"Nat Mater"},{"key":"418_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-bioeng-071811-150124","volume":"14","author":"A Albanese","year":"2012","unstructured":"Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1\u201316. https:\/\/doi.org\/10.1146\/annurev-bioeng-071811-150124.","journal-title":"Annu Rev Biomed Eng"},{"key":"418_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev-pharmtox-010611-134623","volume":"52","author":"SM Moghimi","year":"2012","unstructured":"Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol. 2012;52:481\u2013503. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010611-134623.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"12","key":"418_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nnano.2012.207","volume":"7","author":"MP Monopoli","year":"2012","unstructured":"Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012;7(12):779\u201386. https:\/\/doi.org\/10.1038\/nnano.2012.207.","journal-title":"Nat Nanotechnol"},{"key":"418_CR33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","volume":"66","author":"N Bertrand","year":"2014","unstructured":"Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2\u201325. https:\/\/doi.org\/10.1016\/j.addr.2013.11.009.","journal-title":"Adv Drug Deliv Rev"},{"issue":"13","key":"418_CR34","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","volume":"66","author":"DB Kirpotin","year":"2006","unstructured":"Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13):6732\u201340. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4199.","journal-title":"Cancer Res"},{"key":"418_CR35","volume-title":"Drug products, including biological products, that contain nanomaterials: guidance for industry","author":"US Food and Drug Administration","year":"2022","unstructured":"US Food and Drug Administration. Drug products, including biological products, that contain nanomaterials: guidance for industry. Silver Spring: FDA; 2022."},{"key":"418_CR36","volume-title":"Liposome drug products: chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation: guidance for industry","author":"US Food and Drug Administration","year":"2018","unstructured":"US Food and Drug Administration. Liposome drug products: chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation: guidance for industry. Silver Spring: FDA; 2018."},{"key":"418_CR37","volume-title":"Nanotechnology-based medicinal products for human use in the EU: horizon scanning report","author":"European Medicines Agency","year":"2025","unstructured":"European Medicines Agency. Nanotechnology-based medicinal products for human use in the EU: horizon scanning report. Amsterdam: EMA; 2025."},{"issue":"12","key":"418_CR38","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1016\/j.xphs.2024.09.005","volume":"113","author":"JD Clogston","year":"2024","unstructured":"Clogston JD, Foss W, Harris D, et al. Current state of nanomedicine drug products: an industry perspective. J Pharm Sci. 2024;113(12):3395\u2013405. https:\/\/doi.org\/10.1016\/j.xphs.2024.09.005.","journal-title":"J Pharm Sci"},{"key":"418_CR39","volume-title":"ICH Q8(R2): Pharmaceutical Development","author":"International Council for Harmonisation","year":"2009","unstructured":"International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. Geneva: ICH; 2009."},{"key":"418_CR40","volume-title":"ICH Q9(R1): Quality Risk Management","author":"International Council for Harmonisation","year":"2023","unstructured":"International Council for Harmonisation. ICH Q9(R1): Quality Risk Management. Geneva: ICH; 2023."},{"key":"418_CR41","volume-title":"ICH Q10: Pharmaceutical Quality System","author":"International Council for Harmonisation","year":"2008","unstructured":"International Council for Harmonisation. ICH Q10: Pharmaceutical Quality System. Geneva: ICH; 2008."},{"issue":"31","key":"418_CR42","doi-asserted-by":"publisher","first-page":"11449","DOI":"10.1073\/pnas.1411393111","volume":"111","author":"JE Zuckerman","year":"2014","unstructured":"Zuckerman JE, Gritli I, Tolcher A, et al. Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci U S A. 2014;111(31):11449\u201354. https:\/\/doi.org\/10.1073\/pnas.1411393111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"418_CR43","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-15-2548","volume":"22","author":"DD Von Hoff","year":"2016","unstructured":"Von Hoff DD, Mita MM, Ramanathan RK, et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin Cancer Res. 2016;22(13):3157\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2548.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"418_CR44","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","volume":"4","author":"KA Autio","year":"2018","unstructured":"Autio KA, Dreicer R, Anderson J, et al. Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol. 2018;4(10):1344\u201351. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2168.","journal-title":"JAMA Oncol"},{"issue":"9","key":"418_CR45","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","volume":"119","author":"P Munster","year":"2018","unstructured":"Munster P, Krop IE, LoRusso P, et al. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer. 2018;119(9):1086\u201393. https:\/\/doi.org\/10.1038\/s41416-018-0235-2.","journal-title":"Br J Cancer"},{"issue":"4","key":"418_CR46","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s10637-012-9921-8","volume":"31","author":"GJ Weiss","year":"2013","unstructured":"Weiss GJ, Chao J, Neidhart JD, et al. First-in-human phase 1\/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical, in patients with advanced solid tumor malignancies. Invest New Drugs. 2013;31(4):986\u20131000. https:\/\/doi.org\/10.1007\/s10637-012-9921-8.","journal-title":"Invest New Drugs"},{"issue":"2","key":"418_CR47","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","volume":"35","author":"MS Beg","year":"2017","unstructured":"Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35(2):180\u20138. https:\/\/doi.org\/10.1007\/s10637-016-0407-y.","journal-title":"Invest New Drugs"},{"issue":"31","key":"418_CR48","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/jco.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794\u2013803. https:\/\/doi.org\/10.1200\/jco.2005.04.937.","journal-title":"J Clin Oncol"},{"issue":"18","key":"418_CR49","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1211\/pj.2013.11129176","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1211\/pj.2013.11129176.","journal-title":"N Engl J Med"},{"key":"418_CR50","unstructured":"US Food and Drug Administration. ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension): highlights of prescribing information. NDA 021660, revised August 2020. Silver Spring: US Food and Drug Administration; 2020. Food and Drug Administration. Abraxane (paclitaxel protein-bound particles for injectable suspension) prescribing information. Silver Spring: FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021660s047lbl.pdf.US."},{"key":"418_CR51","unstructured":"US Food and Drug Administration. ONIVYDE (irinotecan liposome injection), for intravenous use: highlights of prescribing information. NDA 207793, revised December 2024. Silver Spring: US Food and Drug Administration; 2024. Food and Drug Administration. Onivyde (irinotecan liposome injection) prescribing information. Silver Spring: FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/207793s018lbl.pdf.US."},{"key":"418_CR52","unstructured":"US Food and Drug Administration. VYXEOS (daunorubicin and cytarabine) liposome for injection, for intravenous use: highlights of prescribing information. NDA 209401, revised January 2026. Silver Spring: US Food and Drug Administration; 2026. Accessed 9 Oct 2026US Food and Drug Administration. Vyxeos (daunorubicin and cytarabine liposome for injection) prescribing information. Silver Spring: FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/209401s018lbl.pdf."},{"key":"418_CR53","volume-title":"Fyarro (sirolimus protein-bound particles for injectable suspension) prescribing information","author":"US Food and Drug Administration","year":"2021","unstructured":"US Food and Drug Administration. FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), for intravenous use: highlights of prescribing information. NDA 213312, revised September 2026. Silver Spring: US Food and Drug Administration; 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/213312s014lbl.pdf."},{"key":"418_CR54","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.addr.2020.09.009","volume":"156","author":"D Hwang","year":"2020","unstructured":"Hwang D, Ramsey JD, Kabanov AV. Polymeric micelles for the delivery of poorly soluble drugs: from nanoformulation to clinical approval. Adv Drug Deliv Rev. 2020;156:80\u2013118. https:\/\/doi.org\/10.1016\/j.addr.2020.09.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"418_CR55","volume-title":"Apealea: European public assessment report and withdrawal information","author":"European Medicines Agency","year":"2024","unstructured":"European Medicines Agency. Apealea: European public assessment report and withdrawal information. Amsterdam: EMA; 2024."},{"issue":"3","key":"418_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/IJN.S595","volume":"3","author":"JU Junghanns","year":"2008","unstructured":"Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed. 2008;3(3):295\u2013309. https:\/\/doi.org\/10.2147\/IJN.S595.","journal-title":"Int J Nanomed"},{"issue":"3","key":"418_CR57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/157016311796799062","volume":"8","author":"RH Muller","year":"2011","unstructured":"Muller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol. 2011;8(3):207\u201327. https:\/\/doi.org\/10.2174\/157016311796799062.","journal-title":"Curr Drug Discov Technol"},{"key":"418_CR58","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jconrel.2017.03.008","volume":"252","author":"Y Singh","year":"2017","unstructured":"Singh Y, Meher JG, Raval K, et al. Nanoemulsion: concepts, development and applications in drug delivery. J Control Release. 2017;252:28\u201349. https:\/\/doi.org\/10.1016\/j.jconrel.2017.03.008.","journal-title":"J Control Release"},{"issue":"2","key":"418_CR59","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. https:\/\/doi.org\/10.1002\/jev2.12404.","journal-title":"J Extracell Vesicles"},{"issue":"5","key":"418_CR60","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41416-019-0391-z","volume":"120","author":"Y Fujiwara","year":"2019","unstructured":"Fujiwara Y, Mukai H, Saeki T, et al. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br J Cancer. 2019;120(5):475\u201380. https:\/\/doi.org\/10.1038\/s41416-019-0391-z.","journal-title":"Br J Cancer"},{"key":"418_CR61","unstructured":"US Food and Drug Administration. DOXIL (doxorubicin hydrochloride liposome injection), for intravenous use: highlights of prescribing information. NDA 050718, revised March 2026. Silver Spring: US Food and Drug Administration; 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/050718s064lbl.pdf."},{"issue":"2","key":"418_CR62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","volume":"61","author":"J Szebeni","year":"2014","unstructured":"Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 2014;61(2):163\u201373. https:\/\/doi.org\/10.1016\/j.molimm.2014.06.038.","journal-title":"Mol Immunol"},{"issue":"14","key":"418_CR63","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1158\/1078-0432.CCR-16-1990","volume":"23","author":"RK Ramanathan","year":"2017","unstructured":"Ramanathan RK, Korn RL, Raghunand N, et al. Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: a pilot study. Clin Cancer Res. 2017;23(14):3638\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1990.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"418_CR64","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-010-0389-0","volume":"103","author":"K Maier-Hauff","year":"2011","unstructured":"Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317\u201324. https:\/\/doi.org\/10.1007\/s11060-010-0389-0.","journal-title":"J Neurooncol"},{"issue":"8","key":"418_CR65","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","volume":"20","author":"S Bonvalot","year":"2019","unstructured":"Bonvalot S, Rutkowski PL, Thariat J, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2\u20133, randomised, controlled trial. Lancet Oncol. 2019;20(8):1148\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(19)30326-2.","journal-title":"Lancet Oncol"},{"key":"418_CR66","volume-title":"Onpattro (patisiran) lipid complex injection prescribing information","author":"US Food and Drug Administration","year":"2018","unstructured":"US Food and Drug Administration. ONPATTRO (patisiran) lipid complex injection, for intravenous use: highlights of prescribing information. NDA 210922, revised January 2023. Silver Spring: US Food and Drug Administration; 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/210922s012lbl.pdf."},{"issue":"7","key":"418_CR67","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc A, Querbes W, De S, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357\u201364. https:\/\/doi.org\/10.1038\/mt.2010.85.","journal-title":"Mol Ther"},{"issue":"5","key":"418_CR68","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s11095-010-0073-2","volume":"27","author":"V Filipe","year":"2010","unstructured":"Filipe V, Hawe A, Jiskoot W. Critical evaluation of nanoparticle tracking analysis for particle sizing and concentration measurement. Pharm Res. 2010;27(5):796\u2013810. https:\/\/doi.org\/10.1007\/s11095-010-0073-2.","journal-title":"Pharm Res"},{"key":"418_CR69","doi-asserted-by":"publisher","first-page":"461767","DOI":"10.1016\/j.chroma.2020.461767","volume":"1635","author":"F Caputo","year":"2021","unstructured":"Caputo F, Mehn D, Clogston JD, Rosslein M, Prina-Mello A, Borgos SE, et al. Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals: the joint view of EUNCL and NCI-NCL. J Chromatogr A. 2021;1635:461767. https:\/\/doi.org\/10.1016\/j.chroma.2020.461767.","journal-title":"J Chromatogr A"},{"issue":"492","key":"418_CR70","doi-asserted-by":"publisher","first-page":"eaav8521","DOI":"10.1126\/scitranslmed.aav8521","volume":"11","author":"OPB Wiklander","year":"2019","unstructured":"Wiklander OPB, Brennan MA, Lotvall J, Breakefield XO, El Andaloussi S. Advances in therapeutic applications of extracellular vesicles. Sci Transl Med. 2019;11(492):eaav8521. https:\/\/doi.org\/10.1126\/scitranslmed.aav8521.","journal-title":"Sci Transl Med"},{"issue":"7659","key":"418_CR71","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498\u2013503. https:\/\/doi.org\/10.1038\/nature22341.","journal-title":"Nature"},{"issue":"5","key":"418_CR72","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","volume":"20","author":"DJ Irvine","year":"2020","unstructured":"Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020;20(5):321\u201334. https:\/\/doi.org\/10.1038\/s41577-019-0269-6.","journal-title":"Nat Rev Immunol"},{"key":"418_CR73","doi-asserted-by":"publisher","first-page":"102741","DOI":"10.1016\/j.nantod.2025.102741","volume":"63","author":"R Ye","year":"2025","unstructured":"Ye R, Ren Q, Chang L, et al. Administration route-commended concise organ-selective mRNA transfection (ACCOST) by cyclic disulfide-primed short polyethylenimine. Nano Today. 2025;63:102741. https:\/\/doi.org\/10.1016\/j.nantod.2025.102741.","journal-title":"Nano Today"},{"key":"418_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-026-01672-0","author":"Q Ren","year":"2026","unstructured":"Ren Q, Zhao X, Zhou L, et al. Polymer-mRNA complexes for monocyte-trafficked, lymph node-targeted cancer vaccination. Nat Biomed Eng. 2026. https:\/\/doi.org\/10.1038\/s41551-026-01672-0.","journal-title":"Nat Biomed Eng"},{"issue":"41","key":"418_CR75","doi-asserted-by":"publisher","first-page":"eadn9961","DOI":"10.1126\/sciadv.adn9961","volume":"10","author":"T Fan","year":"2024","unstructured":"Fan T, Xu C, Wu J, et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity. Sci Adv. 2024;10(41):eadn9961. https:\/\/doi.org\/10.1126\/sciadv.adn9961.","journal-title":"Sci Adv"},{"issue":"52","key":"418_CR76","doi-asserted-by":"publisher","first-page":"e2109256118","DOI":"10.1073\/pnas.2109256118","volume":"118","author":"SA Dilliard","year":"2021","unstructured":"Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci U S A. 2021;118(52):e2109256118. https:\/\/doi.org\/10.1073\/pnas.2109256118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"418_CR77","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313\u201320. https:\/\/doi.org\/10.1038\/s41565-020-0669-6.","journal-title":"Nat Nanotechnol"},{"issue":"10","key":"418_CR78","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nnano.2013.181","volume":"8","author":"S Tenzer","year":"2013","unstructured":"Tenzer S, Docter D, Kuharev J, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772\u201381. https:\/\/doi.org\/10.1038\/nnano.2013.181.","journal-title":"Nat Nanotechnol"},{"issue":"11","key":"418_CR79","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","volume":"7","author":"RK Jain","year":"2010","unstructured":"Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653\u201364. https:\/\/doi.org\/10.1038\/nrclinonc.2010.139.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"418_CR80","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nmat3792","volume":"12","author":"VP Chauhan","year":"2013","unstructured":"Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat Mater. 2013;12(11):958\u201362. https:\/\/doi.org\/10.1038\/nmat3792.","journal-title":"Nat Mater"},{"issue":"7","key":"418_CR81","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nbt.2612","volume":"31","author":"J Gilleron","year":"2013","unstructured":"Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31(7):638\u201346. https:\/\/doi.org\/10.1038\/nbt.2612.","journal-title":"Nat Biotechnol"},{"key":"418_CR82","volume-title":"Analytical procedures for mRNA vaccine quality (draft guidelines)","author":"United States Pharmacopeia","year":"2024","unstructured":"United States Pharmacopeia. Analytical procedures for mRNA vaccine quality (draft guidelines). 3rd ed. Rockville: USP; 2024.","edition":"3"},{"issue":"10","key":"418_CR83","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Kariko K, Tureci O. mRNA-based therapeutics: developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759\u201380. https:\/\/doi.org\/10.1038\/nrd4278.","journal-title":"Nat Rev Drug Discov"},{"key":"418_CR84","volume-title":"PAT: a framework for innovative pharmaceutical development, manufacturing, and quality assurance","author":"US Food and Drug Administration","year":"2004","unstructured":"US Food and Drug Administration. PAT: a framework for innovative pharmaceutical development, manufacturing, and quality assurance. Silver Spring: FDA; 2004."},{"key":"418_CR85","volume-title":"Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management","author":"International Council for Harmonisation. ICH Q12","year":"2019","unstructured":"International Council for Harmonisation. ICH Q12. Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Geneva: ICH; 2019."},{"key":"418_CR86","volume-title":"Comparability of Biotechnological\/Biological Products Subject to Changes in their Manufacturing Process","author":"International Council for Harmonisation. ICH Q5E","year":"2004","unstructured":"International Council for Harmonisation. ICH Q5E. Comparability of Biotechnological\/Biological Products Subject to Changes in their Manufacturing Process. Geneva: ICH; 2004."},{"issue":"3","key":"418_CR87","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"418_CR88","doi-asserted-by":"publisher","first-page":"437971","DOI":"10.1155\/2014\/437971","volume":"2014","author":"AS Ibrahim","year":"2014","unstructured":"Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. https:\/\/doi.org\/10.1155\/2014\/437971.","journal-title":"J Cancer Epidemiol"},{"issue":"1","key":"418_CR89","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Ma S, Cui H, et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat Commun. 2024;15(1):6305. https:\/\/doi.org\/10.1038\/s41467-024-50619-z.","journal-title":"Nat Commun"},{"issue":"7","key":"418_CR90","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41563-024-01867-3","volume":"23","author":"B Li","year":"2024","unstructured":"Li B, Raji IO, Gordon AGR, et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat Mater. 2024;23(7):1002\u20138. https:\/\/doi.org\/10.1038\/s41563-024-01867-3.","journal-title":"Nat Mater"},{"key":"418_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02490-y","author":"J Witten","year":"2024","unstructured":"Witten J, Raji I, Manan RS, et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02490-y.","journal-title":"Nat Biotechnol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00418-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00418-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00418-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:48:28Z","timestamp":1792144108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00418-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["418"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00418-y","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"31 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study did not involve human participants, animals, or plants, and therefore no ethics approval or informed consent was required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"79"}}